Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure

Heart

Volumn 92, Issue 11, 2006, Pages 1603-1609

  Strey, C H ^b   Young, J M ^a   Lainchbury, J H ^a   Frampton, C M ^a   Nicholls, M G ^c   Richards, A M ^a   Scott, Russell S ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ATORVASTATIN; ATRIAL NATRIURETIC FACTOR; CHOLESTEROL; ENDOTHELIN 1; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; N(G) METHYLARGININE; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY HEMODYNAMICS; DOSE RESPONSE; ECHOCARDIOGRAPHY; ENDOCRINE DISEASE; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART FAILURE; HUMAN; ISCHEMIA; MALE; PRIORITY JOURNAL;

BIOLOGICAL MARKERS; CHOLESTEROL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; ENDOTHELIUM, VASCULAR; FEMALE; HEART FAILURE, CONGESTIVE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; PYRROLES; VASCULAR RESISTANCE; VASODILATION;

EID: 33750357691     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.082560     Document Type: Article

References (53)

1. Kubo SH, Rector TS, Bank AJ, et al. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991;84:1589-96.
2. Drexler H. Endothelium as a therapeutic target in heart failure. Circulation 1998;98:2652-5.
3. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000;356:930-3.
4. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002;39:1567-73.
5. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31.
6. Vogel RA, Corretti MC, Plotnick GD. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1990;77:37-40.
7. Vogel RA. Cholesterol lowering and endothelial Function. Am J Med 1999;107:479-87.
8. Marchesi S, Lupattelli G, Siepi D, et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 2000;36:617-21.
9. John S, Delles C, Jacobi J, et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001;37:1351-8.
10. Willenheimer R, Erhardt LR. Value of 6-min-walk test for assessment of severity and prognosis of heart failure. Lancet 2000;355:515-6.
11. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992;124:1017-25.
12. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
13. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65.
14. Pignoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986;74:1399-406.
15. Watts GF, O'Brien SF, Silvester W, et al. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin Sci (Lond) 1996;91:567-73.
16. Benjamin N, Calver A, Collier J, et al. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995;25:918-23.
17. Yandle TG, Espiner EA, Nicholls MG, et al. Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. J Clin Endocrinol Metab 1986;63:72-9.
18. Yandle TG, Richards AM, Gilbert A, et al. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993;76:832-8.
19. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994;343:440-4.
20. Wright SP, Prickett TC, Doughty RN, et al. Amino-terminal pro-C-type natriuretic peptide in heart failure. Hypertension 2004;43:94-100.
21. Evans JJ, Youssef AH, Yandle TG, et al. Effects of endothelin-1 on release of adrenomedullin and C-type natriuretic peptide from individual human vascular endothelial cells. J Endocrinol 2002;175:225-32.
22. Lewis LK, Smith MW, Yandle TG, et al. Adrenomedullin(1-52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. Clin Chem 1998;44:571-7.
23. Goldstein DS, Feuerstein G, Izzo JL Jr, et al. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci 1981;28:467-75.
24. Sahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
25. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
26. Schiller NB, Acquatella H, Ports TA, et al. Left ventricular volume from paired biplane two-dimensional echocardiography. Circulation 1979;60:547-55.
27. Laufs U, Wassmann S, Schackmann S, et al. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol 2004;93:103-8.
28. Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 2005;91:27-31.
29. Engelke KA, Halliwill JR, Proctor DN, et al. Contribution of nitric oxide and prostaglandins to reactive hyperemia in human forearm. J Appl Physiol 1996;81:1807-14.
30. Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108:839-43.
31. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-82.
32. Davidson MH. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation 2005;111:2280-1.
33. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109:III39-43.
34. Von Hoehling S, Anker SD, Bassenge E. Statins and the role of nitric oxide in chronic heart failure. Heart Fail Rev 2003;8:99-106.
35. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-35.
36. Feron O, Dessy C, Desager JP, et al. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001;103:113-8.
37. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-9.
38. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356-63.
39. Levin ER. Endothelins. N Engl J Med 1995;333:356-63.
40. Parker JD, Thiessen JJ. Increased endothelin-1 production in patients with chronic heart failure. Am J Physiol Heart Circ Physiol 2004;286:H1141-5.
41. Rademaker MT, Charles O, Espiner EA, et al. Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure. Clin Sci (Lond) 2004;106:569-76.
42. Wilkins MR, Redondo J, Brown LA. The natriuretic-peptide family. Lancet 1997;349:1307-10.
43. Chen HH, Burnett JC Jr. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 1998;32(Suppl 3):S22-8.
44. Chun TH, Itoh M, Ogawa Y, et al. Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension 1997;29:1296-302.
45. Totsune K, Takahashi K, Murakami O, et al. Elevated plasma C-type natriuretic peptide concentrations in patients with chronic renal failure. Clin Sci (Lond) 1994;87:319-22.
46. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-40.
47. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990;87:8931-4.
48. Mortensen SA Vadhanavikit S, Folkers K. Deficiency of coenzyme Q10 in myocardial failure. Drugs Exp Clin Res 1984;10:497-502.
49. Strey CH, Young JM, Molyneux SL, et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 2005;179:201-6.
50. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004;93:1124-9.
51. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004;43:642-8.
52. Sola S, Mir MQ, Rajagopalan S, et al. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail 2005;11:607-12.
53. Fukuta H, Sane DC, Brucks S, et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005;112:357-63.